The global erythropoietin drugs market is expected to grow at a significant CAGR 9.5% during the forecast period (2022-2028). Hematopoietin medications are also known as erythropoietin drugs. It's a glycoprotein hormone that controls erythropoiesis, or RBC creation. They are used to treat a variety of illnesses, including cancer, chronic kidney disease, AIDS, anaemia, and many more. When one or more of these factors are present, erythropoietin medications may fail to achieve an effective therapeutic response. Vitamin B12 or folate deficit, occult blood loss and/or iron deficiency Infection and inflammation are two terms used interchangeably. 

Erythropoietin drugs market is to be driven by new product launches and patent expiration during the forecast period. Darbepoetin-alfa is a novel erythropotine drug created by Amgen, Inc. and marketed under the Aranesp brand name. In the US, this pharmaceutical substance has a patent that expires in 2024. Darbepoetin-alfa is likely to be beneficial in the future owing to its higher efficiency and lengthy half-life. At the conclusion of the stage of renal disease, this is a viable way for treating anaemia induced by renal disease. Darbepoetin-alfa is being studied in new therapeutic sectors, with the potential to serve the global erythropoietin medicines market with significant growth potential.

The market has been divided into epoetin alfa, epoetin beta, and others based on pharmacological class. Epoetin alfa is expected to hold a prominent share in the global erythropoietin drugs market during the forecast period. The attributable factors for the growth of the segment are that epoetin alfa is commonly linked to cancer treatment and chronic kidney failure. Thus, the rising prevalence of cancer and chronic kidney failure is contributing to the growth of the segment. According to the International Agency for Research on Cancer, bladder disease is the sixth most prevalent cancer diagnosed in men and the ninth leading cause of cancer mortality in the world in 2018. In the past, bladder cancer has been linked to a lack of patient awareness. According to the National Institute of Health, the patient's lifetime cost in the US ranges from $96,000 to $187,000. According to the American Cancer Society, 9 out of 10 patients diagnosed with this cancer in the US are over the age of 55. When persons are diagnosed, they are on average 73 years old.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Drug Class 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Amgen Inc., Johnson & Johnson Services, Inc., and Pfizer Inc., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Erythropoietin Drugs Market Report by Segment

By Drug Class 

• Epoetin Alfa

• Epoetin Beta

• Others

By Application

• Hematology

• Kidney Disorder

• Cancer

• Others

Global Erythropoietin Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa